| TITLE |
DATE |
| MannKind to Present at Upcoming Conferences |
8-Nov-2011 |
| MannKind Corporation Reports 2011 Third Quarter Financial Results |
3-Nov-2011 |
| MannKind Corporation to Hold 2011 Third Quarter Financial Results Conference Call on November 3, 2011 |
28-Oct-2011 |
| MannKind to Present at The 18th Annual Newsmakers in the BioTech Industry Conference |
14-Oct-2011 |
| MannKind Announces Proposed Offering of Senior Secured Discount Notes
Due 2017 |
23-Sep-2011 |
| MannKind to Present at Upcoming Conferences |
22-Sep-2011 |
| MannKind to Present at Rodman & Renshaw Annual Global Investment Conference |
6-Sep-2011 |
| MannKind Confirms Design of Pivotal Studies |
11-Aug-2011 |
| MannKind Corporation Reports 2011 Second Quarter Financial Results |
4-Aug-2011 |
| MannKind Corporation to Hold 2011 Second Quarter Financial ResultsConference Call on August 4, 2011 |
28-Jul-2011 |
| Studies Show No Increased Risk of Cardiac Events in Diabetes Patients Treated with AFREZZA(R) |
24-Jun-2011 |
| Type 1 Diabetes Patients Using AFREZZA Have More Positive View of Therapy Compared to Standard Insulin Therapy |
24-Jun-2011 |
| MannKind to Present at the Wells Fargo Securities 2011 Healthcare Conference |
16-Jun-2011 |
| MannKind to Present at the Jefferies 2011 Global Healthcare Conference |
31-May-2011 |
| MannKind Corporation Reports 2011 First Quarter Financial Results |
9-May-2011 |
| MannKind to Present at Upcoming Conferences |
26-Apr-2011 |
| MannKind Corporation to Hold 2011 First Quarter Financial Results Conference Call on May 9, 2011 |
19-Apr-2011 |
| MannKind's End-of-Review Meeting with FDA Rescheduled |
12-Apr-2011 |
| MannKind Provides Regulatory Update |
8-Apr-2011 |
| MannKind Posters Win Awards from International Pharmaceutical Aerosol Consortium on Regulation and Science |
5-Apr-2011 |
| MannKind to Present at the Citi 2011 Global Healthcare Conference |
22-Feb-2011 |
| MannKind Corporation Reports 2010 Fourth Quarter and Full Year Financial Results |
10-Feb-2011 |
| MannKind to Present at the 13th Annual BIO CEO & Investor Conference |
8-Feb-2011 |
| MannKind Corporation to Hold 2010 Fourth Quarter and Full Year Financial Results Conference Call on February 10, 2011 |
27-Jan-2011 |
| MannKind Corporation Receives Complete Response Letter from the FDA
for AFREZZA(R) |
19-Jan-2011 |
| MannKind to Present at the JP Morgan 29th Annual Healthcare Conference |
4-Jan-2011 |
| MannKind Updates Status of New Drug Application for AFREZZA(R) |
28-Dec-2010 |
| Presentation at American Society of Hematology Annual Meeting Confirms Inhibiting Unfolded Protein Response is Promising Treatment for Multiple Myeloma |
7-Dec-2010 |
| MannKind to Present at the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference |
1-Dec-2010 |
| New Findings Show Bioequivalence, Ease-of-Use and Efficiency of MannKind's Drug Delivery Platform |
15-Nov-2010 |
| MannKind to Present at the Lazard Capital Markets 7th Annual Healthcare Conference |
9-Nov-2010 |
| MannKind Corporation Issues Statement on Lawsuit |
4-Nov-2010 |
| MannKind Corporation Reports 2010 Third Quarter Financial Results |
29-Oct-2010 |
| MannKind Corporation to Hold 2010 Third Quarter Financial Results Conference Call on October 29, 2010 |
22-Oct-2010 |
| MannKind Announces Initiation of Phase 2 Trial of Cancer Vaccine for Advanced Melanoma |
19-Oct-2010 |
| MannKind to Present at Upcoming Conferences |
7-Sep-2010 |
| MannKind Corporation Providing AFREZZA(R) to Juvenile Diabetes Research Foundation for Artificial Pancreas Project |
23-Aug-2010 |
| MannKind Announces Entry into Stock Lending Agreement |
19-Aug-2010 |
| MannKind Announces Pricing of $100 Million Senior Convertible Notes |
19-Aug-2010 |
| MannKind Announces Proposed Offering of Common Stock and Related
Share Lending Arrangement |
16-Aug-2010 |
| MannKind Announces Proposed Offering of $100 Million Senior
Convertible Notes |
16-Aug-2010 |
| MannKind Receives Commitment to Purchase Up to 18,200,000 Shares of
Common Stock for Cash |
11-Aug-2010 |
| MannKind Receives Commitment from The Mann Group to Reduce
Indebtedness in Return for Up to 18,200,000 Shares of Common Stock |
11-Aug-2010 |
| MannKind to Present at the 30th Annual
Canaccord Genuity Growth Conference |
4-Aug-2010 |
| MannKind's Chairman and CEO Recognized as One of PharmaVOICE's "100
Most Inspiring People in the Life Sciences" |
3-Aug-2010 |
| MannKind Corporation Reports 2010 Second Quarter Financial Results |
2-Aug-2010 |
| MannKind Corporation to Hold 2010 Second Quarter Financial Results Conference Call on August 2, 2010 |
26-Jul-2010 |
| FDA Accepts AFREZZA Complete Response Resubmission and Sets Target
Action Date |
20-Jul-2010 |
| AFREZZA(R) Demonstrates Long-Term Efficacy in Controlling Blood Sugar Levels in Patients with Type 2 Diabetes |
28-Jun-2010 |
| AFREZZA(R) Suppresses Endogenous Glucose Production More Rapidly Than Currently Available Insulin Therapy |
26-Jun-2010 |
| American Diabetes Association/The Lancet Symposium Will Highlight Study Showing AFREZZA(R) Provides Comparable Glycemic Control with Less Weight Gain and Hypoglycemia than Standard of Care |
24-Jun-2010 |
| AFREZZA Demonstrates Non-Inferiority Compared to Standard Therapy in
Controlling Blood Sugar Levels in Type 1 Diabetes Patients |
10-Jun-2010 |
| MannKind to Present at Upcoming Conferences and Annual Stockholders
Meeting |
2-Jun-2010 |
| MannKind Corporation Reports 2010 First Quarter Financial Results |
30-Apr-2010 |
| MannKind to Present at Upcoming Conferences |
27-Apr-2010 |
| MannKind Corporation to Hold 2010 First Quarter Financial Results
Conference Call on April 30, 2010 |
23-Apr-2010 |
| Follow-up Safety Data Show AFREZZA(R) Comparable to Standard Antidiabetic Therapy in Lung Function Tests |
23-Apr-2010 |
| Study Shows AFREZZA(R) Controls Blood Sugar Levels in Type 1 Diabetes, Results in Weight Loss, Less Hypoglycemia Than Usual Care |
23-Apr-2010 |
| MannKind Corporation Achieves All Milestones of Research Agreement
with Multiple Myeloma Research Foundation to Develop New Therapy |
29-Mar-2010 |
| MannKind Corporation Wins Prestigious Frost & Sullivan
Entrepreneurial Company of the Year Award |
24-Mar-2010 |
| FDA Requests Additional Information Regarding AFREZZA(TM) in Complete
Response Letter to MannKind |
15-Mar-2010 |
| MannKind Elects James S. Shannon to its Board of Directors |
24-Feb-2010 |
| MannKind to Present at the 12th Annual BIO CEO & Investor Conference |
2-Feb-2010 |
| MannKind Corporation Reports 2009 Fourth Quarter and Full Year Financial Results |
1-Feb-2010 |
| MannKind Corporation to Hold 2009 Fourth Quarter and Full Year Financial Results Conference Call on February 1, 2010 |
25-Jan-2010 |
| MannKind Wins Two Facility of the Year 2010 Category Awards |
11-Jan-2010 |
| MannKind Updates Status of New Drug Application |
8-Jan-2010 |
| MannKind to Present at the 28th Annual J.P.
Morgan Healthcare Conference |
5-Jan-2010 |
| CORRECTING and REPLACING MannKind Corporation Reports Third Quarter Financial Results |
2-Nov-2009 |
| MannKind to Present at Upcoming Conferences |
2-Nov-2009 |
| MannKind Corporation Reports Third Quarter Financial Results |
2-Nov-2009 |
| Studies Show Early Promise of MannKind's Cancer Immunotherapy Program in Melanoma, Prostate Cancer and Other Solid Malignancies |
29-Oct-2009 |
| MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 2, 2009 |
26-Oct-2009 |
| AFRESA(R) Phase 3 Data Show Sustained Glycemic Control, Normal Lung Function in Patients over Four Years of Treatment |
2-Oct-2009 |
| MannKind to Present at the Fourth Annual JMP Securities Healthcare Focus Conference |
29-Sep-2009 |
| Study Shows AFRESA(R) Provides Rapid Suppression of Endogenous Glucose Production in Diabetes Patients |
29-Sep-2009 |
| MannKind to Present at Upcoming Conferences |
3-Sep-2009 |
| MannKind Announces Completion of Common Stock Offering |
10-Aug-2009 |
| MannKind to Present at the 29th Annual Canaccord Adams Global Growth Conference |
6-Aug-2009 |
| MannKind Announces Pricing of Public Offering of Common Stock |
5-Aug-2009 |
| MannKind Corporation Reports Second Quarter Financial Results |
3-Aug-2009 |
| MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 3, 2009 |
27-Jul-2009 |
| MannKind Announces Positive New Market Survey Information Regarding AFRESA(R) |
14-Jul-2009 |
| MannKind Closes Acquisition of Insulin Assets from Pfizer |
22-Jun-2009 |
| MannKind Unveils Next-Generation Inhalation System |
8-Jun-2009 |
| AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA |
6-Jun-2009 |
| Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients |
6-Jun-2009 |
| MannKind to Present at the Needham Life Sciences Conference |
3-Jun-2009 |
| FDA Accepts MannKind's Submission and Files NDA for AFRESA |
18-May-2009 |
| MannKind to Present at the Canaccord Adams Diabetes and Obesity Conference |
5-May-2009 |
| MannKind Corporation Reports First Quarter of 2009 Financial Results |
4-May-2009 |
| MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 4, 2009 |
27-Apr-2009 |
| MannKind Submits NDA for AFRESA for Treatment of Diabetes |
16-Mar-2009 |
| MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant |
9-Mar-2009 |
| MannKind Updates Status of NDA Submission for AFRESA |
26-Feb-2009 |
| MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results |
17-Feb-2009 |
| MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009 |
11-Feb-2009 |
| MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference |
2-Feb-2009 |
| MannKind Reports Successful Completion of Device Bioequivalence Trial |
13-Jan-2009 |
| MannKind to Present at the 27th Annual J.P. Morgan Healthcare Conference |
19-Dec-2008 |
| MannKind Reports Top-Line Results from Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes |
18-Dec-2008 |
| MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes |
15-Dec-2008 |
| MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes |
4-Dec-2008 |
| MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference |
25-Nov-2008 |
| MannKind Corporation Reports Third Quarter Financial Results |
5-Nov-2008 |
| MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference |
3-Nov-2008 |
| MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008 |
29-Oct-2008 |
| MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility |
17-Sep-2008 |
| MannKind and Pfizer Announce Collaboration for Certain Exubera Patients to Transition to MannKind's Inhaled Insulin Therapy |
16-Sep-2008 |
| MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes |
16-Sep-2008 |
| MannKind to Present at the UBS Global Life Sciences Conference |
15-Sep-2008 |
| MannKind Corporation to Host Webcast Analyst Day September 16, 2008 |
11-Sep-2008 |
| MannKind Corporation Reports Second Quarter Financial Results |
11-Aug-2008 |
| MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008 |
4-Aug-2008 |
| MannKind to Present at Upcoming Conferences |
16-Jun-2008 |
| MannKind to Present at Upcoming Conferences |
7-May-2008 |
| MannKind Corporation Reports First Quarter Financial Results |
5-May-2008 |
| The Leukemia & Lymphoma Society and MannKind Corporation Announce Collaborative Research Agreement |
5-May-2008 |
| MannKind to Present at the Morgan Stanley Healthcare Conference |
28-Apr-2008 |
| MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008 |
28-Apr-2008 |
| Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer |
16-Apr-2008 |
| MannKind Addresses Pfizer's Announcement Regarding Exubera |
10-Apr-2008 |
| MannKind to Present at the Cowen and Company Healthcare Conference |
13-Mar-2008 |
| MannKind Corporation Response to Recent Market Events |
10-Mar-2008 |
| MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results |
4-Mar-2008 |
| MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008 |
28-Feb-2008 |
| MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference |
1-Feb-2008 |
| MannKind to Present at the Wachovia 2008 Healthcare Conference |
25-Jan-2008 |
| John R. Riesenberger Joins MannKind as Corporate Vice President and Chief Commercialization Officer |
7-Jan-2008 |
| MannKind to Present at the JP Morgan Healthcare Conference |
2-Jan-2008 |
| MannKind to Present at the Piper Jaffray Healthcare Conference |
20-Nov-2007 |
| MannKind Corporation Reports Third Quarter Financial Results |
7-Nov-2007 |
| MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation |
5-Nov-2007 |
| MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 7, 2007 |
5-Nov-2007 |
| MannKind to Present at Upcoming Conferences |
1-Nov-2007 |
| MannKind Announces New $350 Million Credit Facility |
2-Oct-2007 |
| MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock |
2-Oct-2007 |
| MannKind to Present at the UBS Global Life Sciences Conference |
18-Sep-2007 |
| MannKind Corporation Reports Second Quarter Financial Results |
9-Aug-2007 |
| MannKind Second Quarter Financial Results Conference Call on August 9, 2007 |
8-Aug-2007 |
| MannKind to Hold Investor Call Tomorrow; 2Q Release Next Week |
2-Aug-2007 |
| MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 3, 2007 |
26-Jul-2007 |
| MannKind Resolves Litigation With Former Employee |
15-Jun-2007 |
| MannKind to Present at the Needham & Company Biotechnology & Medical Technology Conference |
7-Jun-2007 |
| MannKind to Present at the Bank of America 2007 Health Care Conference |
24-May-2007 |
| MannKind Corporation Reports First Quarter Financial Results |
11-May-2007 |
| MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 11, 2007 |
7-May-2007 |
| MannKind to Present at the UBS Global Generic and Specialty Pharmaceuticals Conference |
4-May-2007 |
| MannKind to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference |
4-Apr-2007 |
| MannKind to Present at Cowen and Company 27th Annual Health Care Conference |
5-Mar-2007 |
| MannKind Corporation Reports Fourth Quarter and Full Year 2006 Financial Results |
2-Feb-2007 |
| Frost & Sullivan Acknowledges MannKind's Path-Breaking Solution to Treat Diabetes |
1-Feb-2007 |
| MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 2, 2007 |
31-Jan-2007 |
| MannKind to Present at Leerink Swann & Company Diabetes Roundtable Conference |
30-Jan-2007 |
| MannKind to Present at Upcoming Healthcare Conferences |
12-Jan-2007 |
| MannKind to Present at 25th Annual JPMorgan Healthcare Conference |
2-Jan-2007 |
| MannKind Corporation Announces Exercise in Full of Common Stock Offering Over-Allotment Option |
18-Dec-2006 |
| MannKind Corporation Announces Completion of Concurrent Public Offerings of Common Stock and Senior Convertible Notes |
12-Dec-2006 |
| MannKind Corporation Announces Pricing of Concurrent Public Offerings of Common Stock and Senior Convertible Notes |
7-Dec-2006 |
| MannKind Corporation Announces Proposed Concurrent Public Offerings of Common Stock and Senior Convertible Notes |
27-Nov-2006 |
| MannKind Corporation Announces Clearance of IND for MKC1106-PP Immunotherapy in Solid Malignancies |
27-Nov-2006 |
| MannKind Corporation Reports Third Quarter Financial Results |
2-Nov-2006 |
| MannKind Announces Third Quarter Results Release Date, Conference Call and Upcoming Events |
26-Oct-2006 |
| Type 2 Diabetes Patients on Technosphere Insulin Exhibited No Adverse Effect on Pulmonary Function with Significant HbA1c Reductions, and Showed Significant Weight Reduction Compared to Injected Insulin Analog |
18-Sep-2006 |
| MannKind Corporation Completes Patient Enrollment for the Major Phase 3 Safety Study of Technosphere(R) Insulin in Patients With Diabetes |
14-Sep-2006 |
| MannKind to Present at Upcoming Conferences |
14-Sep-2006 |
| MannKind Corporation Reports Second Quarter Financial Results |
3-Aug-2006 |
| MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 3, 2006 |
27-Jul-2006 |
| MannKind to Present at Upcoming Conferences |
13-Jun-2006 |
| MannKind to Present at Pacific Growth Equities 2006 Life Sciences Growth Conference |
8-Jun-2006 |
| MannKind to Present at Rodman & Renshaw 3rd Annual Global Healthcare Conference |
9-May-2006 |
| MannKind Corporation Reports First Quarter Financial Results |
5-May-2006 |
| MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2006 |
28-Apr-2006 |
| Type 1 Diabetes Patients on Technosphere Insulin Showed HbA1c Improvements, Low Post-Prandial Glucose Fluctuations, and Weight Loss |
19-Apr-2006 |
| MannKind to Present at UBS Global Specialty Pharmaceutical Conference |
17-Apr-2006 |
| MannKind to Webcast Investor Day Presentations |
5-Apr-2006 |
| MannKind to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference |
28-Mar-2006 |
| MannKind Initiates Two U.S. Pivotal Phase 3 Studies of Inhaled Technosphere(R) Insulin |
6-Mar-2006 |
| MannKind to Present at Cowen & Co. 26th Annual Health Care Conference |
1-Mar-2006 |
| MannKind to Present at Citigroup Global Healthcare Conference |
21-Feb-2006 |
| MannKind Corporation Announces Issuance of Two Key U.S. Patents |
8-Feb-2006 |
| MannKind Corporation Reports Fourth Quarter and Full Year 2005 Financial Results |
6-Feb-2006 |
| MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 6, 2006 |
30-Jan-2006 |
| MannKind Corporation Announces Positive Results From a Phase 2b Dose-Ranging Study of Technosphere(R) Insulin in Patients With Type 2 Diabetes |
17-Jan-2006 |
| MannKind to Present at Upcoming Healthcare Conferences |
1-Nov-2005 |
| MannKind Corporation Reports Third Quarter Financial Results |
24-Oct-2005 |
| MannKind Corporation Announces Addition of Key Executives |
24-Oct-2005 |
| MannKind to Present at C.E. Unterberg, Towbin Life Sciences Conference |
18-Oct-2005 |
| MannKind Corporation to Hold Third Quarter Financial Results Conference Call on October 24, 2005 |
17-Oct-2005 |
| MannKind to Present at UBS 2005 Global Life Sciences Conference |
20-Sep-2005 |
| MannKind Corporation Files Registration Statement For Recently Completed Private Placement |
2-Sep-2005 |
| MannKind to Present at Oppenheimer Diabetes Conference |
31-Aug-2005 |
| MannKind Announces Dr. Adrian Bot Appointed Editor-in-Chief of International Reviews in Immunology |
22-Aug-2005 |
| MannKind Corporation Announces $175 Million Private Financing |
3-Aug-2005 |
| MannKind Corporation Reports Second Quarter Financial Results |
28-Jul-2005 |
| MannKind Corporation to Hold Second Quarter Financial Results Conference Call on July 28, 2005 |
21-Jul-2005 |
| MannKind Initiates U.S. Pivotal Phase 3 Study of Inhaled Technosphere(R) Insulin |
29-Jun-2005 |
| MannKind to Present at 15th Annual Wachovia Securities Nantucket Equity Conference |
22-Jun-2005 |
| MannKind Presents Safety and Efficacy Data on Inhaled Technosphere(R) Insulin at American Diabetes Association's 65th Scientific Sessions |
14-Jun-2005 |
| MannKind Reports Inhaled Technosphere(R) Insulin Data at American Diabetes Association's 65th Scientific Sessions |
11-Jun-2005 |
| MannKind Corporation to Present Data on Inhaled Technosphere(R) Insulin at the American Diabetes Association's 65th Scientific Sessions |
6-Jun-2005 |
| MannKind Corporation Added to NASDAQ Biotechnology Index |
16-May-2005 |
| MannKind Corporation Reports First Quarter Financial Results |
6-May-2005 |
| MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 6 |
3-May-2005 |
| MannKind to Present at BioCentury Future Leaders in the Biotech Industry Conference |
1-Apr-2005 |
| Henry L. Nordhoff Joins Board of Directors of MannKind Corporation |
18-Mar-2005 |
| Mannkind Corporation Reports Fourth Quarter Financial Results |
3-Feb-2005 |
| MannKind Corporation to Hold Conference Call Regarding Fourth Quarter Financial Results |
27-Jan-2005 |
| MannKind to Present at Brean Murray Institutional Investor Conference |
26-Jan-2005 |
| MannKind to Present at Piper Jaffray 2005 Health Care Conference |
18-Jan-2005 |
| MannKind Reports Positive Data From Its US Phase 2b Clinical Trial of Technosphere(R) Insulin in Type 2 Diabetes Mellitus and Commences First Phase 3 Clinical Trial in Europe |
22-Dec-2004 |
| MannKind to Present at Harris Nesbitt Focus on Healthcare 2004 Conference |
1-Dec-2004 |
| MannKind Provides Update on Technosphere Insulin System |
10-Nov-2004 |
| MannKind to Present at CIBC World Markets Fifteenth Annual Healthcare Conference |
5-Nov-2004 |
| MannKind Reports Third Quarter Financial Results |
3-Nov-2004 |
| MannKind to Present at UBS Global Life Sciences Conference |
24-Sep-2004 |
| MannKind Presents Data on Unique Properties of Its Technosphere(R)/Insulin Therapy |
6-Sep-2004 |
| MannKind Reports Second Quarter Financial Results |
1-Sep-2004 |
| MannKind Corporation Announces Pricing of Initial Public Offering |
28-Jul-2004 |
| MannKind Corporation Announces Launch of Initial Public Offering |
14-Jul-2004 |
| Mannkind Corporation Files Registration Statement for Proposed Initial Public Offering of Common Stock |
30-Apr-2004 |
| MannKind Corporation Completes $50 Million Private Placement |
11-Mar-2004 |
| MannKind Corporation initiates Feasibility Study with Novo Nordisk A/S on Pulmonary Formulation of Therapeutic Protein |
14-Nov-2003 |
 |
